User: Guest  Login
Title:

The DKTK EXLIQUID consortium exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients

Document type:
Review
Author(s):
Mack, Matthias; Broche, Julian; George, Stephen; Hajjari, Zahra; Janke, Florian; Ranganathan, Lavanya; Ashouri, Mohammadreza; Bleul, Sabine; Desuki, Alexander; Engels, Cecilia; Fliedner, Stephanie M. J.; Hartmann, Nils; Hummel, Michael; Janning, Melanie; Kiel, Alexander; Koehler, Thomas; Koschade, Sebastian; Lablans, Martin; Lambarki, Mohamed; Loges, Sonja; Lueong, Smiths; Meyer, Sandra; Ossowski, Stephan; Scherer, Florian; Schroeder, Christopher; Skowronek, Patrick; Thiede, Christian; Uhl, Barb...     »
Abstract:
Testing for genetic alterations in tumor tissue allows clinicians to identify patients who most likely will benefit from molecular targeted treatment. EXLIQUID - exploiting liquid biopsies to advance cancer precision medicine - investigates the potential of additional non-invasive tools for guiding therapy decisions and monitoring of advanced cancer patients. The term "liquid biopsy" (LB) refers to non-invasive analysis of tumor-derived circulating material such as cell-free DNA in blood samples...     »
Journal title abbreviation:
J. Lab. Med.
Year:
2022
Journal volume:
46
Journal issue:
4
Pages contribution:
321-330
Fulltext / DOI:
doi:10.1515/labmed-2022-0071
Print-ISSN:
2567-9430
TUM Institution:
1036; Institut für Klinische Chemie und Pathobiochemie
 BibTeX